Status:

UNKNOWN

GENe EXpression After Regional or General ANesthesia in Patients Undergoing Breast Cancer Surgery

Lead Sponsor:

Azienda Ospedaliera San Gerardo di Monza

Conditions:

Breast Cancer Female

Eligibility:

FEMALE

18-85 years

Phase:

NA

Brief Summary

Breast cancer is the most commonly diagnosed cancer in females and the second leading cause of death from cancer in women. It was estimated that 2 million new cases have occurred in 2018 worldwide 1. ...

Detailed Description

Background: Exposure to general or regional anesthesia, can modulate differently breast cancer biology through a direct activity on cancer cells or indirectly through modifications in host response (i...

Eligibility Criteria

Inclusion

  • Women 18-85 years old
  • No undergoing pregnancy
  • ASA Score I-IV
  • Patients scheduled for breast surgery
  • No contraindications (including surgical) to regional (paravertebral) anesthesia
  • No previous breast surgery
  • No known hereditary or familial cancer syndromes
  • No previous cancer anamnesis, radio o chemiotherapy
  • Primary breast cancer with Tumor classification 1-3, Nodes 0-2 as determined
  • according to the NCI stage definitions (Primary breast cancer without known extension beyond the breast and axillary nodes)
  • Free from pain in preoperative period
  • Patients who don't use analgesic drugs before surgery
  • Patients without cognitive impairment or mental retardation

Exclusion

  • Women \> 18, \< 85 years old
  • Pregnancy
  • ASA Score \> IV
  • Previous breast surgery
  • Contraindications to regional anesthesia
  • Known hereditary or familial cancer syndromes
  • Previous cancer anamnesis, radio or chemiotherapy
  • Tumor classification \> 3, Nodes \> 2, M \> 0 as determined according to the NCI stage
  • definitions
  • Pain in preoperative period
  • Use of analgesic drugs before surgery
  • Cognitive impairment or mental retardation
  • Patients who did not gave a written informed consent
  • Undergoing therapy with alpha (doxazosin) or beta blockers.

Key Trial Info

Start Date :

March 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2022

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT03779685

Start Date

March 1 2021

End Date

March 1 2022

Last Update

August 5 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.